Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 16/20 | 0.54 |
| ▸ | PDE4A | P27815 | 4/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29259224 | 0.88 | NPC1 (0.56) | NPC1LMNAHTTPDE4BPDE4A | |
| SCHEMBL570575 | 0.84 | LMNA (0.75) | NPC1LMNAHTTCYP1A2CYP3A4 | |
| SCHEMBL28968086 | 0.81 | PDE4B (0.63) | PDE4BPDE4APDE4CPDE4DCYP1A2 | |
| SCHEMBL13412905 | 0.81 | CA5A (0.57) | NPC1PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL17980660 | 0.80 | LMNA (0.58) | NPC1LMNAHTTPDE4BPDE4A | |
| SCHEMBL28325671 | 0.79 | PDE4B (0.56) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL28324553 | 0.79 | PDE4B (0.56) | NPC1LMNAHTTPDE4BPDE4A | |
| SCHEMBL29259233 | 0.78 | PDE4B (0.62) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL30601064 | 0.78 | PDE4B (0.62) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL1031663 | 0.78 | CA12 (0.63) | PDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3777979-B1 | ANTI-INFLAMMATORY COMPOUND AND PREPARATION AND USE THEREOF | E NITIATE BIOPHARMACEUTICALS HANGZHOU CO LTD (CN) | 2024-01-17 | — | — | EP | disclosed |
| US-11440886-B2 | Anti-inflammatory compound, and preparation and use thereof | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. (CN) | 2022-09-13 | — | — | US | disclosed |
| EP-3777979-A1 | ANTI-INFLAMMATORY COMPOUND AND PREPARATION AND USE THEREOF | Vivavision Biotech, Inc. (CN) | 2021-02-17 | — | — | EP | disclosed |
| US-20200377460-A1 | ANTI-INFLAMMATORY COMPOUND, AND PREPARATION AND USE THEREOF | VIVAVISION BIOTECH, INC. (CN) | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11440886-B2 | Anti-inflammatory compound, and preparation and use thereof | PDE4B, PDE4A, PDE7A | NPC1 4359/4885LMNA 3960/4885HTT 4831/4885 |
| US-20200377460-A1 | ANTI-INFLAMMATORY COMPOUND, AND PREPARATION AND USE THEREOF | PDE4B, PDE4A, PDE7A | NPC1 4359/4885LMNA 3960/4885HTT 4831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.